"Muscarinic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
| Descriptor ID |
D018727
|
| MeSH Number(s) |
D27.505.519.625.120.200.500 D27.505.696.577.120.200.500
|
| Concept/Terms |
Muscarinic Antagonists- Muscarinic Antagonists
- Antagonists, Muscarinic
- Antimuscarinics
- Antimuscarinic Agents
- Agents, Antimuscarinic
- Cholinergic Muscarinic Antagonists
- Antagonists, Cholinergic Muscarinic
- Muscarinic Antagonists, Cholinergic
|
Below are MeSH descriptors whose meaning is more general than "Muscarinic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Muscarinic Antagonists".
This graph shows the total number of publications written about "Muscarinic Antagonists" by people in this website by year, and whether "Muscarinic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Muscarinic Antagonists" by people in Profiles.
-
Li H, Zhang G, Forsythe E, Okamoto LE, Yu X. Implications of Antimuscarinic Autoantibodies in Postural Tachycardia Syndrome. J Cardiovasc Transl Res. 2022 Apr; 15(2):438-440.
-
Liu Y, Scherlag BJ, Fan Y, Xia W, Huang H, Po SS. Acetylcholine-Atropine Interactions: Paradoxical Effects on Atrial Fibrillation Inducibility. J Cardiovasc Pharmacol. 2017 Jun; 69(6):369-373.
-
Siatkowski RM. Myopia prevention: Newton is still right. J AAPOS. 2015 Dec; 19(6):494-5.
-
Po SS, Scherlag BJ. CFAE: "I know it when I see it!" But what does it mean? J Cardiovasc Electrophysiol. 2012 Jan; 23(1):34-5.
-
Lu Z, Scherlag BJ, Lin J, Yu L, Guo JH, Niu G, Jackman WM, Lazzara R, Jiang H, Po SS. Autonomic mechanism for initiation of rapid firing from atria and pulmonary veins: evidence by ablation of ganglionated plexi. Cardiovasc Res. 2009 Nov 01; 84(2):245-52.
-
Siatkowski RM, Cotter SA, Crockett RS, Miller JM, Novack GD, Zadnik K. Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS. 2008 Aug; 12(4):332-9.
-
Siatkowski RM, Cotter S, Miller JM, Scher CA, Crockett RS, Novack GD. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol. 2004 Nov; 122(11):1667-74.
-
Scherlag BJ, Yamanashi WS, Schauerte P, Scherlag M, Sun YX, Hou Y, Jackman WM, Lazzara R. Endovascular stimulation within the left pulmonary artery to induce slowing of heart rate and paroxysmal atrial fibrillation. Cardiovasc Res. 2002 May; 54(2):470-5.
-
Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002 Feb; 22(2):240-50.
-
Levin DC, Little KS, Laughlin KR, Galbraith JM, Gustman PM, Murphy D, Kram JA, Hardie G, Reuter C, Ostransky D, McFarland K, Petty TL, Silvers W, Rennard SI, Mueller M, Repsher LH, Zuwallack RL, Vale R. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med. 1996 Jan 29; 100(1A):40S-48S.